trending Market Intelligence /marketintelligence/en/news-insights/trending/Rb8AaWa7SefmH4LzCz4qKA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

US FDA to act on Nabriva's resubmitted application for Contepo

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


US FDA to act on Nabriva's resubmitted application for Contepo

The U.S. Food and Drug Administration acknowledged Nabriva Therapeutics PLC's resubmission of an application for injectable medicine Contepo to treat complicated urinary tract infections after a prior rejection.

Dublin-based Nabriva is seeking approval of Contepo to treat complicated urinary tract infections including acute pyelonephritis, a type of urinary tract infection that usually begins in the bladder and travels to one or both kidneys.

An initial application for Contepo was previously rejected by the FDA due to issues regarding facility inspections and manufacturing deficiencies. No new clinical data was requested by the regulator.

The regulator will make a decision on the application by June 19.

Contepo is an injection-administered antibiotic that works by improving the absorption and effects of fosfomycin, which was originally approved in Europe over 45 years ago to treat a variety of infections.